Susquehanna International Group’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$993K Sell
28,582
-2,316
-7% -$68.4K ﹤0.01% 8222
2026
Q1
$713K Sell
30,898
-211,930
-87% -$4.79M ﹤0.01% 8773
2025
Q4
$4.89M Buy
+242,828
New +$5.05M ﹤0.01% 4055
2025
Q3
– Sell
-29,611
Closed -$582K – 14106
2025
Q2
$645K Sell
29,611
-7,180
-20% -$149K ﹤0.01% 8579
2025
Q1
$680K Buy
36,791
+18,955
+106% +$464K ﹤0.01% 8214
2024
Q4
$475K Buy
+17,836
New +$512K ﹤0.01% 8785

Other funds holding AVBP

Susquehanna International Group's AVBP Position: Q2 2026 in Review

Susquehanna International Group reduced its ArriVent BioPharma (AVBP) stake by 7.5% in Q2 2026, selling an estimated $68.4K and leaving 28,582 shares worth $993K. The position accounts for ﹤0.01% of the portfolio, ranked #8222.

Susquehanna International Group first reported a position in AVBP in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.89M in Q4 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Susquehanna International Group held 28,582 shares of ArriVent BioPharma worth $993K as of Q2 2026.
  • Susquehanna International Group sold 2,316 ArriVent BioPharma shares in Q2 2026, an estimated $68.4K.
  • ArriVent BioPharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #8222 holding.
  • Susquehanna International Group first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 6 quarters since.
  • Susquehanna International Group's ArriVent BioPharma position peaked at $4.89M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.